Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 42Terminated 10Unknown 3Withdrawn 1Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

vactosertib 1fludarabine phosphate 1aldesleukin 1Specimen Handling 1Interleukin-2 1IL32 protein, human 1Cyclophosphamide 1CVnCoV COVID-19 vaccine 1COH04S1 COVID-19 vaccine 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Leukemia, Lymphocytic, Chronic, B-Cell × Alemtuzumab × Clear all
NCT01982175 2022-06-21

CLL004

Shanghai Zhangjiang Biotechnology Limited Company

Phase 2 Suspended
120 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡